Last reviewed · How we verify
Opium tincture
Opium tincture contains alkaloids (primarily morphine and codeine) that bind to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and antidiarrheal effects.
Opium tincture contains alkaloids (primarily morphine and codeine) that bind to opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and antidiarrheal effects. Used for Moderate pain, Diarrhea (historically; limited modern use).
At a glance
| Generic name | Opium tincture |
|---|---|
| Also known as | Dropizol |
| Sponsor | Asbjørn Mohr Drewes |
| Drug class | Opioid analgesic |
| Target | Mu opioid receptor (primary); delta and kappa opioid receptors (secondary) |
| Modality | Small molecule |
| Therapeutic area | Pain management; Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The active alkaloids in opium tincture act as agonists at mu, delta, and kappa opioid receptors, modulating pain perception and emotional response to pain in the central nervous system. These compounds also reduce gastrointestinal motility and secretion, making opium tincture historically useful for diarrhea management. The sedative and anxiolytic properties result from opioid receptor activation in the brain.
Approved indications
- Moderate pain
- Diarrhea (historically; limited modern use)
Common side effects
- Constipation
- Drowsiness
- Nausea
- Respiratory depression
- Dependence and tolerance
Key clinical trials
- Opium Tincture Against Chronic Diarrhea - Patients (PHASE2)
- Prospective Randomized Open Label Study of the Treatment of Therapy-associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium - (PHASE3)
- Opium Tincture Against Chronic Diarrhea - Healthy (NA)
- Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder (PHASE3)
- A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals (PHASE3)
- A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 (PHASE3)
- Treatment of Neonatal Abstinence Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |